Gopa Iyer

24.6k total citations · 5 hit papers
159 papers, 4.4k citations indexed

About

Gopa Iyer is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Gopa Iyer has authored 159 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Surgery, 56 papers in Oncology and 55 papers in Molecular Biology. Recurrent topics in Gopa Iyer's work include Bladder and Urothelial Cancer Treatments (110 papers), Urinary and Genital Oncology Studies (53 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Gopa Iyer is often cited by papers focused on Bladder and Urothelial Cancer Treatments (110 papers), Urinary and Genital Oncology Studies (53 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Gopa Iyer collaborates with scholars based in United States, Spain and Germany. Gopa Iyer's co-authors include David B. Solit, Hikmat Al‐Ahmadie, Matthew I. Milowsky, Dean F. Bajorin, Michael F. Berger, Irina Ostrovnaya, Bernard H. Bochner, Jonathan E. Rosenberg, Sara E. Wobker and David M. Hyman and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Gopa Iyer

146 papers receiving 4.3k citations

Hit Papers

Intrinsic subtypes of high-grade bladder cancer reflect t... 2012 2026 2016 2021 2014 2012 2018 2018 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
    2014 613 citations Jeffrey S. Damrauer, Katherine A. Hoadley et al. profile →
  2. Genome Sequencing Identifies a Basis for Everolimus Sensitivity
    2012 480 citations Gopa Iyer, Aphrothiti J. Hanrahan et al. Science profile →
  3. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
    2018 374 citations Min Yuen Teo, Irina Ostrovnaya et al. Journal of Clinical Oncology profile →
  4. Genome doubling shapes the evolution and prognosis of advanced cancers
    2018 343 citations Craig M. Bielski, Ahmet Zehir et al. Nature Genetics profile →
  5. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    2023 84 citations Thomas Powles, Begoña P. Valderrama et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gopa Iyer United States 28 2.5k 1.8k 1.5k 1.2k 817 159 4.4k
Kent W. Mouw United States 25 631 0.3× 982 0.6× 995 0.7× 860 0.7× 617 0.8× 117 2.6k
Annick Vieillefond France 33 914 0.4× 2.0k 1.1× 577 0.4× 2.2k 1.9× 912 1.1× 156 3.5k
Jingsong Zhang United States 24 1.0k 0.4× 768 0.4× 1.4k 0.9× 761 0.7× 563 0.7× 124 3.0k
Ashley Cimino‐Mathews United States 37 575 0.2× 924 0.5× 2.2k 1.5× 907 0.8× 922 1.1× 122 3.8k
Hermann Rogatsch Austria 32 624 0.3× 775 0.4× 573 0.4× 1.1k 0.9× 289 0.4× 80 2.6k
Enrico Munari Italy 35 823 0.3× 926 0.5× 1.6k 1.0× 784 0.7× 528 0.6× 107 3.7k
José A. Martínez-Climent Spain 39 608 0.2× 1.9k 1.1× 1.3k 0.9× 483 0.4× 784 1.0× 135 4.5k
Pekka Klemi Finland 30 705 0.3× 737 0.4× 1.1k 0.7× 426 0.4× 878 1.1× 99 3.1k
Michael R. Pins United States 26 729 0.3× 870 0.5× 660 0.4× 801 0.7× 392 0.5× 68 2.3k
Albert J. Kovatich United States 36 909 0.4× 1.2k 0.7× 1.2k 0.8× 1.0k 0.9× 587 0.7× 84 4.1k

Countries citing papers authored by Gopa Iyer

Since Specialization
Citations

This map shows the geographic impact of Gopa Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gopa Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gopa Iyer more than expected).

Fields of papers citing papers by Gopa Iyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gopa Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gopa Iyer. The network helps show where Gopa Iyer may publish in the future.

Co-authorship network of co-authors of Gopa Iyer

This figure shows the co-authorship network connecting the top 25 collaborators of Gopa Iyer. A scholar is included among the top collaborators of Gopa Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gopa Iyer. Gopa Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moy, Andrea P., Stephen W. Dusza, Alison J. Moskowitz, et al.. (2025). Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. The Oncologist. 30(9). 2 indexed citations
2.
Powles, Thomas, Michiel S. van der Heijden, Shilpa Gupta, et al.. (2024). 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Annals of Oncology. 35. S1137–S1138. 13 indexed citations
3.
Gao, Sizhi Paul, Alvin C. Goh, Bernard H. Bochner, et al.. (2024). COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION. Urologic Oncology Seminars and Original Investigations. 42. S55–S55.
4.
Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581. 1 indexed citations
5.
Pant, Shubham, Joon Oh Park, Wu‐Chou Su, et al.. (2024). Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.. Journal of Clinical Oncology. 42(16_suppl). 4121–4121. 1 indexed citations
6.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571. 1 indexed citations
7.
8.
Hensley, Patrick J., Roland Seiler, Harry W. Herr, et al.. (2023). Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1. Urologic Oncology Seminars and Original Investigations. 41(7). 307–312. 1 indexed citations
9.
10.
Makarov, Vladimir, Yvonne Parker, Allen Wang, et al.. (2023). KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer. Cancer Research. 83(6). 814–829. 23 indexed citations
11.
Damrauer, Jeffrey S., Jeffrey A. Klomp, Mi Zhou, et al.. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13(1). 6658–6658. 27 indexed citations
12.
Teo, Min Yuen, Hikmat Al‐Ahmadie, Kenneth Seier, et al.. (2021). Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer. 124(7). 1214–1221. 21 indexed citations
13.
Adib, Elio, Katarzyna Klonowska, Krinio Giannikou, et al.. (2021). Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research. 27(14). 3845–3853. 37 indexed citations
14.
Damrauer, Jeffrey S., Kyle R. Roell, Xuezheng Sun, et al.. (2021). Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 27(16). 4599–4609. 33 indexed citations
15.
McPherson, Victor, Brendan Reardon, Sasinya N. Scott, et al.. (2020). A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma. Cancer. 126(20). 4532–4544. 20 indexed citations
16.
Bielski, Craig M., Ahmet Zehir, Alexander Penson, et al.. (2018). Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics. 50(8). 1189–1195. 343 indexed citations breakdown →
17.
Owczarek, Tomasz B., Takashi Kobayashi, Ricardo J. Ramirez, et al.. (2017). ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research. 77(4). 1035–1046. 12 indexed citations
18.
Teo, Min Yuen, Richard Bambury, Emily C. Zabor, et al.. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research. 23(14). 3610–3618. 189 indexed citations
19.
Scott, Sasinya N., Irina Ostrovnaya, Nancy Bouvier, et al.. (2017). Next‐generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscle‐invasive urothelial carcinoma treated with bacille Calmette‐Guérin. Cancer Cytopathology. 125(6). 416–426. 23 indexed citations
20.
Iyer, Gopa, Aphrothiti J. Hanrahan, Matthew I. Milowsky, et al.. (2012). Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science. 338(6104). 221–221. 480 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kent W. Mouw Breakdown of academic impact, for papers by Annick Vieillefond Breakdown of academic impact, for papers by Jingsong Zhang Breakdown of academic impact, for papers by Ashley Cimino‐Mathews Breakdown of academic impact, for papers by Hermann Rogatsch Breakdown of academic impact, for papers by Enrico Munari Breakdown of academic impact, for papers by José A. Martínez-Climent Breakdown of academic impact, for papers by Pekka Klemi Breakdown of academic impact, for papers by Michael R. Pins Breakdown of academic impact, for papers by Albert J. Kovatich
Rankless by CCL
2026